{"groups":[{"description":"All subjects were males with advanced prostate carcinoma. They were injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects were followed until day 336.\n\nLeuprolide Mesylate: Subcutaneous injection of 50mg Leuprolide Mesylate","id":"FG000","title":"Leuprolide Mesylate 50mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"137"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"137"}],"type":"ITT"},{"achievements":[{"groupId":"FG000","numSubjects":"124"}],"type":"PP"},{"achievements":[{"groupId":"FG000","numSubjects":"31"}],"type":"PK Subgroup"},{"achievements":[{"groupId":"FG000","numSubjects":"122"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}